跳转至内容
Merck
CN

主要文件

查看所有文档

L5025

来氟米特

≥98% (TLC), T cell proliferation inhibitor, powder

别名:

5-甲基异恶唑-4-（4-三氟甲基）羧基苯胺

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C12H9F3N2O2
化学文摘社编号:
75706-12-6
分子量:
270.21
UNSPSC Code:
12352202
PubChem Substance ID:
24278516
NACRES:
NA.77
MDL number:
MFCD00867593
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

来氟米特, Immunosuppressant

Quality Level

200

assay

≥98% (TLC)

form

powder

mp

166.5 °C

solubility

methanol: 19.60-20.40 mg/mL, clear, colorless to faintly yellow

mode of action

enzyme | inhibits

storage temp.

2-8°C

SMILES string

Cc1oncc1C(=O)Nc2ccc(cc2)C(F)(F)F

InChI

1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)

InChI key

VHOGYURTWQBHIL-UHFFFAOYSA-N

Gene Information

human ... DHODH(1723)

Application

由于其免疫抑制作用，来氟米特被发现可用于器官移植 、类风湿关节炎 和其他自身免疫性疾病的治疗。

Biochem/physiol Actions

免疫抑制；抑制 T、B 细胞增殖。活性主要归因于其代谢产物丙二腈衍生物，后者被认为抑制二氢乳清酸脱氢酶（在 新生 嘧啶合成途径中）以及几种蛋白酪氨酸激酶。

Still not finding the right product?

Explore all of our products under 来氟米特

pictograms

Skull and crossbones
GHS06

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
039M4044V
13180905
107M4010V
038M4149V
13180109

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

K F Siemasko et al.
Transplantation, 61(4), 635-642 (1996-02-27)
Leflunomide is an immunosuppressive drug capable of inhibiting cellular and humoral mediated responses in vivo. The mechanism responsible for suppression of B cell antibody responses in vivo has not been identified. In this study we demonstrate that leflunomide functions to
J M Kremer et al.
Clinical and experimental rheumatology, 22(5 Suppl 35), S95-100 (2004-11-24)
Leflunomide was first shown to have disease-modifying properties in a rat model of adjuvant-induced arthritis. Leflunomide has been subsequently used with success in several animal models of tissue and organ allograft and of autoimmune disease including collagen- and adjuvant-induced arthritis
T R Brazelton et al.
Current opinion in immunology, 8(5), 710-720 (1996-10-01)
Among all the new immunosuppressive molecules being investigated either preclinically or clinically, four stand out: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide (and its malononitriloamide analogs). Each drug has distinct mechanisms of immunosuppressive action, and in the past year
查看所有相关文献

全球贸易项目编号

货号GTIN
L5025-25MG04061833957868
L5025-100MG04061832948119